
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2026

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)
60 First Street, 2nd floor, Suite 250
Cambridge, MA
(Address of principal executive offices)

001-39062
(Commission
File Number)

47-2324450
(IRS Employer
Identification No.)

02141
(Zip Code)

Registrant's telephone number, including area code: (617) 468-1999

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.001 per share	KRRO	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The following is a summary of the matters voted on at the 2026 annual meeting of stockholders of Korro Bio, Inc., or Korro, held on June 10, 2026, or the Annual Meeting.

- 1) Korro's stockholders elected each of Nesson Bermingham and Rachel Meyers as Class I directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2029 and each until his or her respective successor has been duly elected and qualified or until his or her earlier death, resignation or removal. The results of the stockholders' vote with respect to the election of the two Class I directors are as follows:

Name	Votes For	Votes Withheld	Broker Non-Votes
Nesson Bermingham	7,468,003	1,576,660	1,875,955
Rachel Meyers	7,368,284	1,676,379	1,875,955

- 2) Korro's stockholders approved, in a non-binding, advisory vote, the compensation of Korro's named executive officers. The results of the stockholders' advisory vote with respect to the compensation of Korro's named executive officers are as follows:

Votes For	Votes Against	Abstain	Broker Non-Votes
9,009,739	27,988	6,936	1,875,955

- 3) Korro's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders' vote with respect to such ratification are as follows:

Votes For	Votes Against	Abstain	Broker Non-Votes
10,917,621	2,738	259	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KORRO BIO, INC.

Date: June 11, 2026

By: /s/ Ram Aiyar

Name: Ram Aiyar

Title: President and Chief Executive Officer and Interim Chief Financial Officer
